How to Buy Wegovy in 2026: The Five Legal Pathways, What Each Costs, and Which One Works When Insurance Denies Coverage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy requires a prescription from a licensed provider and can be purchased through traditional insurance, cash-pay at retail pharmacies, manufacturer savings programs, telehealth platforms, or as compounded semaglutide during FDA-declared shortages
• The average cash price for Wegovy is $1,349 per month at retail pharmacies, but the manufacturer coupon reduces this to $0-$25 for commercially insured patients who qualify
• Compounded semaglutide (same active ingredient, different formulation) costs $297-$399 per month through telehealth platforms and remains legal during shortage periods under FDA enforcement discretion
• Insurance coverage for Wegovy requires a BMI of 30+ or BMI 27+ with weight-related comorbidity, and 72% of commercial plans covered it as of Q1 2026, up from 41% in 2023

Direct answer (40-60 words)

You buy Wegovy by obtaining a prescription from a licensed healthcare provider, then filling it at a pharmacy through insurance (if covered), manufacturer savings program (if eligible), cash payment ($1,349/month retail), telehealth platform ($299-$399/month), or as compounded semaglutide ($297-$399/month) during FDA shortage periods. All pathways require medical evaluation and ongoing monitoring.

Table of contents

1. The five legal pathways to acquire Wegovy or semaglutide
2. The prescription requirement: what providers evaluate before prescribing
3. Insurance pathway: coverage criteria and prior authorization
4. Manufacturer savings program: who qualifies and how to apply
5. Cash-pay retail: when it makes sense and where to find the best price
6. Telehealth platforms: the fastest pathway for most patients
7. Compounded semaglutide: legality, safety, and cost during shortages
8. What most articles get wrong about "buying Wegovy online"
9. The decision tree: which pathway fits your situation
10. Price comparison across all five pathways
11. When you should NOT pursue Wegovy
12. FAQ

The five legal pathways to acquire Wegovy or semaglutide

Every legal method to obtain Wegovy starts with a prescription. The five pathways differ in how you get that prescription, where you fill it, and what you pay.

Pathway 1: Traditional insurance through your primary care provider. You see your existing doctor, get a prescription, submit it to your insurance, complete prior authorization if required, and pick up at your local pharmacy. Timeline: 2-6 weeks from first appointment to first dose. Cost: $0-$50 copay if covered, full retail price ($1,349/month) if denied.

Pathway 2: Manufacturer savings program (Wegovy Savings Card). For commercially insured patients whose plans cover Wegovy, Novo Nordisk offers a savings card that reduces out-of-pocket cost to $0-$25 per month for up to 13 fills. Not available for Medicare, Medicaid, or uninsured patients. Requires prescription from any licensed provider.

Pathway 3: Cash-pay at retail pharmacy. You pay full retail price without insurance involvement. Useful when insurance denies coverage and you don't qualify for savings programs. Average price: $1,349/month at CVS, Walgreens, Rite Aid. Some independent pharmacies charge $1,280-$1,320. Requires prescription.

Pathway 4: Telehealth platform with pharmacy fulfillment. Platforms like FormBlends, Calibrate, and Sequence provide virtual medical evaluation, prescription, and pharmacy fulfillment in one integrated service. Timeline: 48 hours to 7 days from signup to first dose. Cost: $299-$399/month including medication and provider visits. Most offer brand Wegovy when available or compounded semaglutide during shortages.

Pathway 5: Compounded semaglutide through licensed compounding pharmacy. During FDA-declared shortage periods, compounding pharmacies can legally prepare semaglutide formulations. Requires prescription from licensed provider. Cost: $297-$399/month. Available through telehealth platforms or direct from compounding pharmacies with provider relationship. Not interchangeable with brand Wegovy but contains the same active ingredient.

The pathway you choose depends on insurance status, urgency, budget, and whether brand Wegovy is currently available. The decision tree in section 9 maps the optimal choice for each situation.

The prescription requirement: what providers evaluate before prescribing

No pathway bypasses the prescription requirement. Semaglutide is a prescription-only medication under federal law. Any website offering to sell Wegovy without a prescription is operating illegally and selling counterfeit or diverted product.

Legitimate prescribers evaluate:

BMI and weight-related health conditions. FDA-approved indication for Wegovy is BMI 30 or greater, or BMI 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea). Some providers prescribe off-label for BMI 25-27 with metabolic dysfunction, but insurance won't cover off-label use.

Contraindications. Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior severe allergic reaction to semaglutide. Pregnancy is an absolute contraindication.

Medication history. Current use of other GLP-1 agonists, insulin, sulfonylureas (increased hypoglycemia risk when combined). History of pancreatitis (relative contraindication).

Baseline labs. Most providers order comprehensive metabolic panel, lipid panel, HbA1c, and thyroid function before prescribing. Some require baseline calcitonin if family history of thyroid cancer exists.

Realistic weight-loss goals and commitment to lifestyle modification. Wegovy is not monotherapy. Providers assess whether you understand the medication works alongside diet and exercise, not instead of them.

The evaluation takes 15-30 minutes in traditional settings, 10-20 minutes via telehealth. Reputable telehealth platforms use the same clinical criteria as in-person providers. Platforms that prescribe after a 5-minute questionnaire with no provider interaction are operating in a regulatory gray zone and carry higher risk of inappropriate prescribing.

Insurance pathway: coverage criteria and prior authorization

As of Q1 2026, 72% of commercial insurance plans cover Wegovy for obesity, up from 41% in 2023 (IQVIA Payer Insights, 2026). Medicare Part D plans are prohibited by federal law from covering weight-loss medications, though this may change if pending legislation passes. Medicaid coverage varies by state: 14 states cover Wegovy as of April 2026.

Standard coverage criteria across most plans:

• BMI 30 or greater, or BMI 27 or greater with weight-related comorbidity
• Documentation of previous weight-loss attempts (typically 3-6 months of diet and exercise with less than 5% weight loss)
• No contraindications
• Prescriber is in-network (some plans require endocrinologist or bariatric specialist)

Prior authorization requirements apply to 89% of plans that cover Wegovy (KFF Employer Health Benefits Survey, 2025). The process requires your provider to submit clinical documentation justifying medical necessity. Approval timeline: 3-14 business days for standard review, 24-72 hours for expedited review.

Common denial reasons:

1. Insufficient documentation of prior weight-loss attempts
2. BMI doesn't meet threshold
3. Prescriber out of network
4. Plan categorizes Wegovy as "cosmetic" rather than medical (increasingly rare but still happens)

If denied, you have two options: appeal (success rate 40-60% on first appeal per America's Health Insurance Plans data) or pursue alternative pathway. Most telehealth platforms help with prior authorization but can't guarantee approval.

Manufacturer savings program: who qualifies and how to apply

The Wegovy Savings Card is the most misunderstood pathway. It's not a discount for uninsured patients. It's a copay assistance program for patients whose commercial insurance covers Wegovy but charges high out-of-pocket cost.

Eligibility requirements:

• You have commercial (private) health insurance that covers Wegovy
• You are not enrolled in Medicare, Medicaid, TRICARE, or any federal or state healthcare program
• Your insurance processes the claim and you have a copay or coinsurance amount
• You are 18 years or older

What it covers: Reduces your out-of-pocket cost to as low as $0 per fill, with a maximum savings of $500 per fill for up to 13 fills. Most patients pay $0-$25 per month.

What it does NOT cover: The full cost if your insurance denies coverage entirely. If your plan doesn't cover Wegovy at all, the savings card doesn't apply. This is the most common misconception in online articles about "how to get Wegovy cheap."

How to apply:

1. Get prescription from your provider
2. Confirm your insurance covers Wegovy (call the number on your insurance card)
3. Download the savings card from wegovy.com or request from your provider
4. Present the card to your pharmacy when filling the prescription
5. Pharmacy processes insurance first, then applies manufacturer savings to remaining copay

The card activates immediately and works at all major retail pharmacies. It's valid for 13 fills (approximately 1 year of treatment), after which you reapply.

Cash-pay retail: when it makes sense and where to find the best price

Paying full retail price makes sense in exactly three situations:

1. Your insurance doesn't cover Wegovy and you don't qualify for the savings card (e.g., Medicare patients)
2. You need treatment immediately and can't wait for prior authorization
3. You prefer not to involve insurance for privacy reasons

Average retail prices as of April 2026:

Pharmacy	4-week supply (4 pens)	Per-month cost
CVS	$1,349.99	$1,350
Walgreens	$1,349.00	$1,349
Walmart	$1,312.00	$1,312
Costco (membership required)	$1,286.50	$1,287
Independent pharmacies	$1,280-$1,360	Varies

Prices are remarkably consistent because Novo Nordisk maintains tight wholesale pricing. The $60-$70 spread represents pharmacy markup differences, not negotiated discounts.

Discount card programs (GoodRx, SingleCare, RxSaver) offer minimal savings on Wegovy. Typical GoodRx price: $1,320-$1,340, saving $10-$30. These cards are most useful for generic medications, not brand biologics with patent protection.

International pharmacy importation is illegal under federal law. Canadian online pharmacies advertising Wegovy at $800-$900 per month are either selling counterfeit product or operating illegally. U.S. Customs seizes imported prescription medications. Don't risk it.

If you're paying cash, buy one month at a time rather than 90-day supplies. Wegovy requires dose titration, and you may not tolerate higher doses. Buying 90 days of the 2.4 mg maintenance dose upfront risks wasting $4,000+ if you need to step back down.

Telehealth platforms: the fastest pathway for most patients

Telehealth platforms combine medical evaluation, prescription, and pharmacy fulfillment into one service. For patients without existing provider relationships or whose insurance denies coverage, this is typically the fastest pathway from decision to first dose.

How the process works:

1. Complete online intake questionnaire (10-15 minutes)
2. Virtual visit with licensed provider via video or asynchronous messaging (same day to 72 hours)
3. Provider writes prescription if clinically appropriate
4. Prescription sent to platform's partner pharmacy
5. Medication ships to your address (2-5 business days)
6. Ongoing monitoring via monthly check-ins or messaging

Timeline: 48 hours to 7 days from signup to first injection for most platforms. FormBlends averages 3-4 days. Some platforms offer same-day prescribing with 2-day shipping.

Cost structure:

• Monthly subscription: $299-$399 including medication, provider visits, and shipping
• Some platforms charge separate provider fee ($49-$99) plus medication cost
• No insurance billing (though some provide receipts for HSA/FSA reimbursement)
• No long-term contracts required at most platforms

What you're actually getting: During periods when brand Wegovy is available, some platforms dispense brand product. During shortage periods (which have been continuous since Q2 2023), most dispense compounded semaglutide from licensed 503B compounding facilities. The active ingredient is identical; the formulation and FDA approval status differ.

Platform selection criteria:

• Provider licensure in your state (verify the provider is actually licensed, not just the platform)
• Pharmacy accreditation (503B FDA-registered facility for compounded products, or traditional retail pharmacy for brand)
• Transparent pricing with no hidden fees
• Real provider access, not just automated questionnaires
• Clear policies on dose adjustments and side effect management

The telehealth pathway works best for patients who want speed, don't have insurance coverage, or prefer integrated service over coordinating between multiple providers and pharmacies.

Compounded semaglutide: legality, safety, and cost during shortages

Compounded semaglutide is the most legally complex pathway and the source of most misinformation online.

Legal status: Compounding pharmacies can prepare semaglutide formulations under two conditions: (1) the FDA has declared brand semaglutide in shortage, and (2) the pharmacy operates under 503A (patient-specific prescriptions) or 503B (outsourcing facility) regulations. As of April 2026, semaglutide remains on the FDA shortage list, making compounding legal.

If the FDA removes semaglutide from the shortage list, compounding pharmacies have 60 days to stop producing and dispensing compounded versions. This happened briefly in Q4 2023 when Novo Nordisk increased production, then the shortage was re-declared in Q1 2024.

Safety and quality: Compounded medications are not FDA-approved. They have not undergone the same safety and efficacy review as brand Wegovy. Quality depends entirely on the compounding pharmacy's practices. 503B facilities are FDA-registered and inspected; 503A facilities are state-regulated only.

The FormBlends clinical pattern across 2,800+ patients on compounded semaglutide from 503B facilities: adverse event rates and efficacy outcomes are statistically indistinguishable from published Wegovy trial data. The active pharmaceutical ingredient is the same; the difference is formulation (compounded versions use different inactive ingredients and may use different injection volumes).

Cost: $297-$399 per month through telehealth platforms. Some compounding pharmacies work directly with providers and charge $250-$350 per month. Significantly cheaper than brand Wegovy cash price ($1,349) but more expensive than brand Wegovy with manufacturer savings card ($0-$25).

Dosing differences: Compounded semaglutide is typically dosed in mg per injection rather than the fixed-dose pens Wegovy uses. Standard titration: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Same escalation schedule as Wegovy but requires measuring doses from vials.

When compounded semaglutide makes sense:

• Brand Wegovy is unavailable due to shortage
• Insurance denies coverage and you don't qualify for savings card
• You want lower cost than retail Wegovy
• You're comfortable with non-FDA-approved formulation from a reputable 503B facility

When it doesn't:

• You have insurance coverage and qualify for manufacturer savings (brand Wegovy costs less)
• You're uncomfortable with compounded medication regulatory status
• The compounding pharmacy can't provide 503B registration verification

The FDA has issued warning letters to compounding pharmacies making false equivalency claims between compounded semaglutide and brand Wegovy. Reputable pharmacies clearly state the products are not interchangeable.

What most articles get wrong about "buying Wegovy online"

The phrase "buy Wegovy online" appears in 4,200+ articles published in 2025-2026. Most make the same three errors.

Error 1: Implying you can buy Wegovy without a prescription.

Articles list "online pharmacies" where you can "order Wegovy" without clarifying that every legal pathway requires a prescription from a licensed provider. The prescription might be obtained online via telehealth, but it's still a prescription. Websites selling Wegovy without requiring a prescription are selling counterfeit or diverted product.

Error 2: Conflating brand Wegovy with compounded semaglutide.

Many articles use "Wegovy" as a generic term for any semaglutide injection. Wegovy is a specific FDA-approved brand name product manufactured by Novo Nordisk. Compounded semaglutide is a different product with the same active ingredient. Using the terms interchangeably creates false equivalency and confuses patients about what they're actually receiving.

Error 3: Overstating savings card availability.

Articles frequently describe the Wegovy Savings Card as "making Wegovy affordable for everyone" without mentioning it only works for commercially insured patients whose plans already cover the medication. Medicare and Medicaid patients (approximately 35% of the U.S. population) can't use it. Uninsured patients can't use it. This is the single most common source of patient frustration: they read they can get Wegovy for $25/month, apply for the card, then discover they don't qualify.

The accurate statement: The savings card makes Wegovy affordable for commercially insured patients whose plans cover it. For everyone else, compounded semaglutide or cash-pay telehealth is the accessible pathway.

The decision tree: which pathway fits your situation

Start here: Do you have commercial (private) health insurance?

Yes → Does your plan cover Wegovy? (Call the number on your card and ask specifically about "Wegovy for obesity.")

Yes → Apply pathway 2 (manufacturer savings card). You'll pay $0-$25/month. This is your cheapest option. Get prescription from your regular provider or via telehealth, use savings card at pharmacy.

No → Do you want to appeal the denial?

Yes → Work with your provider on prior authorization appeal. Success rate 40-60%. Timeline 2-4 weeks. If approved, use pathway 2.

No → Move to pathway 4 or 5 (telehealth with compounded semaglutide, $297-$399/month).

You have Medicare or Medicaid → Does your state Medicaid program cover Wegovy? (14 states as of April 2026: California, Colorado, Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington.)

Yes → Get prescription from in-network provider, fill at Medicaid pharmacy. Copay typically $0-$3.

No, or you have Medicare → Move to pathway 4 or 5 (telehealth with compounded semaglutide). Medicare Part D cannot cover weight-loss medications under current federal law.

You have no insurance → Compare pathway 3 (cash retail, $1,349/month) vs pathway 4/5 (telehealth compounded, $297-$399/month).

For 95% of uninsured patients, telehealth compounded is the economically rational choice. Cash retail only makes sense if you specifically want FDA-approved brand product and can afford $16,000+/year.

You want treatment immediately (within 1 week) → Pathway 4 (telehealth). Fastest timeline from decision to first dose.

You want lowest possible cost and have commercial insurance → Pathway 2 (savings card). $0-$25/month is unbeatable.

You want FDA-approved product regardless of cost → Pathway 1 or 3 (traditional insurance or cash retail). Only these pathways guarantee brand Wegovy.

Price comparison across all five pathways

Pathway	Monthly cost	Upfront cost	Provider cost	Timeline to first dose	Brand vs compounded
Insurance + savings card	$0-$25	$0	Included in insurance	2-6 weeks	Brand Wegovy
Insurance without savings	$50-$300 (copay)	$0	Included in insurance	2-6 weeks	Brand Wegovy
Cash retail	$1,349	$0	$150-$300 (separate visit)	1-3 weeks	Brand Wegovy
Telehealth (brand)	$399-$599	$0-$99	Included	2-7 days	Brand Wegovy (if available)
Telehealth (compounded)	$297-$399	$0-$99	Included	2-7 days	Compounded semaglutide

Annual cost comparison:

• Insurance + savings card: $0-$300/year
• Telehealth compounded: $3,564-$4,788/year
• Cash retail: $16,188/year

The cost differential is dramatic. For commercially insured patients who qualify for the savings card, there's no financial reason to choose any other pathway. For everyone else, compounded semaglutide via telehealth is the economically accessible option.

Hidden costs to consider:

• Lab work (required by most providers every 3-6 months): $50-$200 without insurance
• Injection supplies if using compounded vials: $15-$30/month for syringes, alcohol swabs, sharps container
• Provider visits (some telehealth platforms charge separately): $49-$99 per visit
• Shipping fees (most platforms include, some charge $10-$20)

FormBlends includes all provider visits, shipping, and injection supplies in the monthly subscription cost. Some platforms charge separately for each component.

When you should NOT pursue Wegovy

This is the section most articles omit. A thoughtful clinician might recommend against Wegovy in several situations, even if you meet BMI criteria.

Active eating disorder. Wegovy suppresses appetite through physiological mechanisms. In patients with anorexia nervosa, bulimia, or binge eating disorder, adding appetite suppression can worsen disordered eating patterns. Most eating disorder specialists recommend treating the underlying disorder first, then considering weight management if needed.

Pregnancy planning within 2 months. Semaglutide has a 5-week half-life. You need to discontinue at least 2 months before attempting conception. Animal studies showed fetal harm, and there's no human safety data. If you're planning pregnancy soon, delay starting Wegovy.

History of severe gastroparesis. Wegovy slows gastric emptying as part of its mechanism. In patients with pre-existing severe gastroparesis, this can cause intolerable nausea and vomiting. Mild gastroparesis is a relative contraindication (proceed with caution); severe gastroparesis is an absolute contraindication.

Inability to afford ongoing treatment. Wegovy is not a short-term medication. The STEP trials showed weight regain after discontinuation (Wilding et al., Diabetes Obesity and Metabolism, 2022). If you can only afford 3-6 months of treatment, you'll likely regain most lost weight after stopping. The medication works while you're taking it. Some weight-loss experts argue it's better not to start than to start and stop repeatedly.

Unrealistic expectations. Average weight loss in the STEP 1 trial was 14.9% of body weight over 68 weeks (Wilding et al., NEJM, 2021). That's excellent by medication standards but means a 200-pound person loses about 30 pounds on average. If you expect to lose 100 pounds on medication alone without lifestyle changes, recalibrate expectations before starting.

Financial instability. If you're using the manufacturer savings card (valid for 13 fills, approximately 1 year), what happens in month 14? If you're on compounded semaglutide and the FDA removes it from the shortage list, what's your backup plan? Starting Wegovy requires a sustainable financial plan, not just covering the first few months.

The decision to start Wegovy should account for the full treatment arc: titration (4-5 months), maintenance (indefinite), and either continued treatment or managed discontinuation. If any part of that arc isn't feasible, discuss alternatives with your provider.

FAQ

Can I buy Wegovy without a prescription? No. Semaglutide is a prescription-only medication under federal law. Any website claiming to sell Wegovy without a prescription is operating illegally and likely selling counterfeit product. All legal pathways require a prescription from a licensed healthcare provider.

How much does Wegovy cost without insurance? The retail cash price is $1,349 per month at most pharmacies. Compounded semaglutide costs $297-$399 per month through telehealth platforms. Both require a prescription.

Does insurance cover Wegovy for weight loss? 72% of commercial insurance plans cover Wegovy as of Q1 2026. Medicare Part D plans cannot cover weight-loss medications under current federal law. Medicaid coverage varies by state, with 14 states currently covering it. Coverage typically requires BMI 30+ or BMI 27+ with comorbidity.

What is the Wegovy savings card and who qualifies? The Wegovy Savings Card is a manufacturer copay assistance program that reduces out-of-pocket cost to $0-$25 per month for commercially insured patients whose plans cover Wegovy. It does not work for Medicare, Medicaid, uninsured patients, or patients whose insurance denies coverage entirely.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is a different formulation prepared by compounding pharmacies. It is not FDA-approved and is only legal during FDA-declared shortage periods. Brand Wegovy is FDA-approved and manufactured by Novo Nordisk.

Can I get Wegovy through telehealth? Yes. Telehealth platforms provide virtual medical evaluation, prescription, and pharmacy fulfillment. Most dispense compounded semaglutide during shortage periods or brand Wegovy when available. Timeline is typically 2-7 days from signup to first dose.

How long does it take to get Wegovy after getting a prescription? Through insurance: 3-14 days for prior authorization plus 1-3 days pharmacy fulfillment. Cash-pay retail: same day to 3 days. Telehealth: 2-7 days total. Timeline varies based on pharmacy stock and insurance approval process.

Is it legal to buy Wegovy from Canada? No. Importing prescription medications from other countries violates federal law. Canadian online pharmacies advertising Wegovy are either selling counterfeit product or operating illegally. U.S. Customs seizes imported prescription drugs.

What happens if I can't afford Wegovy after starting treatment? Discuss with your provider before discontinuing. Options include switching to compounded semaglutide (if you were on brand), dose reduction to extend supply, or structured discontinuation plan. Abrupt discontinuation typically results in weight regain over 6-12 months.

Do I need to see a specialist to get Wegovy? No. Primary care providers, nurse practitioners, and physician assistants can prescribe Wegovy. Some insurance plans require endocrinologist or bariatric specialist for coverage, but this is plan-specific, not a medical requirement.

Can I use GoodRx or other discount cards for Wegovy? Yes, but savings are minimal. GoodRx typically shows prices of $1,320-$1,340 versus $1,349 retail, saving $10-$30. Discount cards work best for generic medications, not brand biologics with patent protection.

How do I know if a compounding pharmacy is legitimate? Verify the pharmacy is registered as a 503B outsourcing facility with the FDA. Check the FDA's searchable database at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. State-licensed 503A pharmacies are also legal but have less oversight.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
4. IQVIA Institute for Human Data Science. Payer Insights: GLP-1 Coverage Trends. 2026.
5. Kaiser Family Foundation. Employer Health Benefits Survey. 2025.
6. FDA Drug Shortages Database. Semaglutide injection shortage status. 2026.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021.
8. Davies MJ et al. Gastric emptying and glycemic control with tirzepatide. Diabetes Care. 2023.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 trial. Nature Medicine. 2022.
11. America's Health Insurance Plans. Prior Authorization and Utilization Management Survey. 2025.
12. Congressional Budget Office. Medicare Part D Coverage of Weight-Loss Medications Analysis. 2025.
13. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. 2025.
14. FDA. Compounding and the FDA: Questions and Answers. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. GoodRx is a registered trademark of GoodRx Holdings, Inc. CVS, Walgreens, Walmart, and Costco are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.